HIGHLIGHTS
- who: Top from the Oklahoma Medical Research Foundation, Oklahoma City, OK, USA Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Oklahoma Health Science have published the Article: for ovarian tumors expressing sfRon receptor, in the Journal: (JOURNAL)
- what: Altogether, the study validates AD80 multi-kinase inhibitor as a promising targeted therapy for sfRonexpressing ovarian tumors. the sfRon plays a superior role to flRon in ovarian cancer progression , in this paper, the authors focus specifically on the sfRon isoform and novel strategies to effectively target this receptor. The authors focused on AKT1 and . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.